Affinia Therapeutics Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
51
- Latest Deal Type
-
Series C
- Latest Deal Amount
-
$40M
- Investors
-
19
Affinia Therapeutics General Information
Description
Developer of an adeno-associated virus gene therapy platform intended to focus on diseases affecting the central nervous system and muscles. The company's platform helps to design therapies using tools and methods such as sequencing technology that was used to map the human genome, artificial intelligence, and structural modeling, enabling medical professionals to get the rational design of vectors and gene therapies with improved properties.
Contact Information
Website
www.affiniatx.comCorporate Office
- 43 Foundry Avenue
- Suite 120
- Waltham, MA 02453
- United States
Corporate Office
- 43 Foundry Avenue
- Suite 120
- Waltham, MA 02453
- United States
Affinia Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Later Stage VC (Series C) | 07-Oct-2025 | $40M | Completed | Generating Revenue | ||
| 3. IPO | 02-Dec-2022 | Cancelled | Generating Revenue | |||
| 2. Early Stage VC (Series B) | 03-May-2021 | $110M | $170M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 12-Mar-2020 | $60M | $60M | Completed | Generating Revenue |
Affinia Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series C | ||||||||
| Series B | ||||||||
| Series A-1 | 23,736,223 | $0.000100 | $2.3 | $2.3 | 1x | $7.7 | 7.93% | |
| Series A | 3,706,187 | $0.000100 | $2.56 | $2.56 | 1x | $8.55 | 1.24% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Affinia Therapeutics Comparisons
Industry
Financing
Details
Affinia Therapeutics Competitors (5)
One of Affinia Therapeutics’s 5 competitors is Orchard Therapeutics, a Formerly VC-backed company based in London, United Kingdom.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Orchard Therapeutics | Formerly VC-backed | London, United Kingdom | ||||
| Autobahn Therapeutics | Venture Capital-Backed | San Diego, CA | ||||
| Voyager Therapeutics | Formerly VC-backed | Lexington, MA | ||||
| Genetix Biotherapeutics | Private Equity-Backed | Somerville, MA | ||||
| ACADIA Pharmaceuticals | Formerly VC-backed | San Diego, CA |
Affinia Therapeutics Patents
Affinia Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026236093-A1 | Methods and compositions for treatment of bag3 mutation-associated dilated cardiomyopathy | Pending | 05-May-2025 | ||
| WO-2026224683-A1 | Recombinant aavs with improved tropism and specificity | Pending | 25-Apr-2025 | ||
| WO-2025235491-A1 | Recombinant aav for treatment of cardiac diseases | Pending | 07-May-2024 | ||
| WO-2025227063-A1 | Recombinant aavs with improved tropism and specificity | Pending | 26-Apr-2024 | ||
| AU-2025235317-A1 | Plasmid system for production of recombinant adenoassociated virus | Pending | 14-Mar-2024 | C12N15/86 |
Affinia Therapeutics Signals
Affinia Therapeutics Investors (19)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Lilly USA | Corporation | Minority | ||
| Avidity Partners | Asset Manager | Minority | ||
| Casdin Capital | Venture Capital | Minority | ||
| EcoR1 Capital | Venture Capital | Minority | ||
| Eight Roads | Corporate Venture Capital | Minority |
Affinia Therapeutics FAQs
-
When was Affinia Therapeutics founded?
Affinia Therapeutics was founded in 2019.
-
Where is Affinia Therapeutics headquartered?
Affinia Therapeutics is headquartered in Waltham, MA.
-
What is the size of Affinia Therapeutics?
Affinia Therapeutics has 51 total employees.
-
What industry is Affinia Therapeutics in?
Affinia Therapeutics’s primary industry is Drug Discovery.
-
Is Affinia Therapeutics a private or public company?
Affinia Therapeutics is a Private company.
-
What is the current valuation of Affinia Therapeutics?
The current valuation of Affinia Therapeutics is .
-
What is Affinia Therapeutics’s current revenue?
The current revenue for Affinia Therapeutics is .
-
How much funding has Affinia Therapeutics raised over time?
Affinia Therapeutics has raised $210M.
-
Who are Affinia Therapeutics’s investors?
Lilly USA, Avidity Partners, Casdin Capital, EcoR1 Capital, and Eight Roads are 5 of 19 investors who have invested in Affinia Therapeutics.
-
Who are Affinia Therapeutics’s competitors?
Orchard Therapeutics, Autobahn Therapeutics, Voyager Therapeutics, Genetix Biotherapeutics, and ACADIA Pharmaceuticals are competitors of Affinia Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process